Literature DB >> 28905489

Consensus and controversies regarding the treatment of rhabdomyosarcoma.

Scott C Borinstein1, Diana Steppan2, Masanori Hayashi2, David M Loeb2, Michael S Isakoff3, Odion Binitie4, Andrew S Brohl4, Julia A Bridge5, Mark Stavas6, Eric T Shinohara6, William H Meyer7, Damon R Reed4, Lars M Wagner8.   

Abstract

Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  adolescent and young adult; chemotherapy; pediatric; rhabdomyosarcoma; sarcoma

Mesh:

Year:  2017        PMID: 28905489     DOI: 10.1002/pbc.26809

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  23 in total

1.  Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.

Authors:  Silvia Codenotti; Maura Poli; Michela Asperti; Daniela Zizioli; Francesco Marampon; Alessandro Fanzani
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-03       Impact factor: 4.553

2.  Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.

Authors:  Jamie M Aye; Yueh-Yun Chi; Jing Tian; Erin R Rudzinski; Odion T Binitie; Roshni Dasgupta; Suzanne L Wolden; Douglas S Hawkins; Abha A Gupta
Journal:  Pediatr Blood Cancer       Date:  2020-03-02       Impact factor: 3.167

3.  SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation.

Authors:  Long Wang; Nicole R Hensch; Kathryn Bondra; Prethish Sreenivas; Xiang R Zhao; Jiangfei Chen; Rodrigo Moreno Campos; Kunal Baxi; Angelina V Vaseva; Benjamin D Sunkel; Berkley E Gryder; Silvia Pomella; Benjamin Z Stanton; Siyuan Zheng; Eleanor Y Chen; Rossella Rota; Javed Khan; Peter J Houghton; Myron S Ignatius
Journal:  Cancer Res       Date:  2021-08-30       Impact factor: 12.701

4.  Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience.

Authors:  Meerim Park; Jun Ah Lee; Hye Young Jin; Joo-Young Kim; Jong Woong Park; June Hyuk Kim; Hyun Guy Kang; Seog Yun Park; Eun Young Park; Hyeon Jin Park; Byung Kiu Park
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-23       Impact factor: 4.322

Review 5.  Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.

Authors:  Jacquelyn N Crane; Wei Xue; Amira Qumseya; Zhengya Gao; Carola A S Arndt; Sarah S Donaldson; Douglas J Harrison; Douglas S Hawkins; Corinne M Linardic; Leo Mascarenhas; William H Meyer; David A Rodeberg; Erin R Rudzinski; Barry L Shulkin; David O Walterhouse; Rajkumar Venkatramani; Aaron R Weiss
Journal:  Pediatr Blood Cancer       Date:  2022-03-06       Impact factor: 3.838

Review 6.  Systemic therapy in pediatric-type soft-tissue sarcoma.

Authors:  K M Ingley; S Cohen-Gogo; A A Gupta
Journal:  Curr Oncol       Date:  2020-02-01       Impact factor: 3.677

Review 7.  Functional and anatomical imaging in pediatric oncology: which is best for which tumors.

Authors:  Stephan D Voss
Journal:  Pediatr Radiol       Date:  2019-10-16

Review 8.  Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer.

Authors:  Tom Curran
Journal:  Open Biol       Date:  2018-08       Impact factor: 6.411

9.  Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome.

Authors:  Matthew Cowan; Tara Suntum; Andrea D Olivas; Melody Perpich; Mark A Applebaum; Ricardo R Lastra; S Diane Yamada
Journal:  Gynecol Oncol Rep       Date:  2018-06-15

10.  A Case of mistaken identity: Rhabdomyosarcoma development from endothelial progenitor cells.

Authors:  Catherine J Drummond; Mark E Hatley
Journal:  Mol Cell Oncol       Date:  2018-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.